phase readout

NCT07667868: A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

NOT_YET_RECRUITINGupdated 2h ago

community read0 votes

Sponsor: BrightPath Biotherapeutics Co., Ltd.. Phase: PHASE1. Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 2h ago

Found something off?